Clinical trial
B-19 Parvovirus Vaccine Study
NCT00379938 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Terminated
Key facts
| NCT number | NCT00379938 |
|---|---|
| Title | B-19 Parvovirus Vaccine Study |
| Official title | A Phase I/II Study of the Safety and Immunogenicity of a Recombinant Human Parvovirus B-19 Vaccine |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Parvovirus B19 Infection |
| Intervention type | Biological, Drug |
| Interventions | VAI-VP705 (parvovirus B-19 vaccine), Placebo, MF-59 |
| Enrollment | 43 |
| Start date | Aug 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Sep 25, 2006 |
| Last update posted | Aug 15, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: